InDex Pharmaceuticals AB Gets New Patent Granted In The U.S.
Published: Nov 03, 2016
STOCKHOLM--(BUSINESS WIRE)--InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
“We are pleased that the USPTO confirms that cobitolimod is a unique and innovative asset for the treatment of refractory ulcerative colitis.”
The patent, entitled Method for prevention of colectomy (patent number 9492516), was filed in 2012 and will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.
“This patent further strengthens and extends our intellectual property position for cobitolimod in the US, which is the most important pharmaceutical market in the world,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “We are pleased that the USPTO confirms that cobitolimod is a unique and innovative asset for the treatment of refractory ulcerative colitis.”
The USPTO has notified the company that the patent will be granted on November 15, 2016. Corresponding patent applications have also been filed in Europe, Japan and Canada and are being diligently prosecuted to grant.
Cobitolimod in brief
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct® and DIMS0150.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on November 3, 2016.
This information was brought to you by Cision http://news.cision.com
Peter Zerhouni, CEO
Phone: +46 8 508 847 35